Home News Intravenous Immunoglobulins Market Research Report 2017 to 2021

Intravenous Immunoglobulins Market Research Report 2017 to 2021


Global Intravenous Immunoglobulins Market Research Report 2017 to 2021 provides a unique tool for evaluating the market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on trends and developments, and focuses on markets and materials, capacities and technologies, and on the changing structure of the Intravenous Immunoglobulins Market.

Companies Mentioned are CSL Behring, Grifols, Octapharma, Shire, ADMA Biologics, Bayer, Bharat Serum and Vaccines, Biotest AG, China Biologic Products, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, and Sanquin.

The global Intravenous Immunoglobulins market consists of different international, regional, and local vendors. The market competition is foreseen to grow higher with the rise in technological innovation and M&A activities in the future. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Major points covered in Global Intravenous Immunoglobulins Market 2017 Research are:-

  • What will the market size and the growth rate be in 2021?
  • What are the key factors driving the global Intravenous Immunoglobulins market?
  • What are the key market trends impacting the growth of the global Intravenous Immunoglobulins market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global Intravenous Immunoglobulins market?
  • What are the market opportunities and threats faced by the vendors in the global Intravenous Immunoglobulins market?
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA.
  • What are the key outcomes of the five forces analysis of the global Intravenous Immunoglobulins market?

This independent 70 page report guarantees you will remain better informed than your competition. With over 150 tables and figures examining the Intravenous Immunoglobulins market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2021.

Get a discount on this report at


Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Intravenous Immunoglobulins in these regions, from 2012 to 2021 (forecast), covering Americas, APAC and EMEA.

The report provides a basic overview of the Intravenous Immunoglobulins industry including definitions, classifications, applications and industry chain structure. And development policies and plans are discussed as well as manufacturing processes and cost structures.

Then, the report focuses on global major leading industry players with information such as company profiles, product picture and specifications, sales, market share and contact information. What’s more, the Intravenous Immunoglobulins industry development trends and marketing channels are analyzed.

Commenting on the report, an analyst from MIR’s team said: “One trend in the market is monetary support to plasma donors. The intravenous immunoglobulin market is growing at steady rate, where the number of plasma donors affects the overall supply chain. Therefore, to maintain and meet the demands of plasma-derived therapeutics, a plasma donor receives monetary compensation.”

According to the report, one driver in the market is growing number of fractionating units. Fractionation is a crucial step in the manufacture of immunoglobulins. This step involves separation of immunoglobulins and other blood protein from plasma. The capacity of fractionating units is increasing. Data estimates suggest that during 2013-2016, the capacity increased by 39.5%. This increased capacity is primarily due to the installment of new fractionating units or expansion of existing fractionating units.

Further, the report states that one challenge in the market is complex and cost-intensive manufacturing. Immunoglobulin manufacturing involves complex, time and cost consuming stages. The process starts from collection of plasma from volunteers. It is followed by plasma fractionation coupled with virus and prion removals. This step is followed by in-vitro testing, which ensures the safety, efficacy and potency of manufactured immunoglobulin.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

The research includes historic data from 2012 to 2016 and forecasts until 2021 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs. The report will make detailed analysis mainly on above questions and in-depth research on the development environment, market size, development trend, operation situation and future development trend of Intravenous Immunoglobulins on the basis of stating current situation of the industry in 2017 so as to make comprehensive organization and judgment on the competition situation and development trend of Intravenous Immunoglobulins Market and assist manufacturers and investment organization to better grasp the development course of Intravenous Immunoglobulins Market.

Inquire for sample copy at